1. Prostate cancer and androgen deprivation therapy {#sec1}
===================================================

Prostate cancer (PCa) growth and recurrence relies on the interaction between the androgen receptor (AR) and testicular ligands, either testosterone (T) or dihydrotestosterone (DHT). Men with advanced PCa receive androgen deprivation therapy (ADT). The goal of ADT is to lower levels of circulating T and impair AR activation in order to induce PCa regression. However, ADT is palliative and PCa recurs as lethal castration-recurrent/resistant PCa (CRPC) [@bib1], [@bib2], [@bib3], [@bib4], [@bib5]. Several mechanisms contribute to PCa persistence during ADT and the transition to CRPC, such as AR mutations, AR hypersensitivity, natural or iatrogenic-induced expression of AR splice variants [@bib6], and intratumoral synthesis of T or DHT [@bib7], [@bib8], [@bib9]. Intratumoral T or DHT synthesis produces tissue T levels similar to androgen-stimulated PCa and benign prostate, and tissue DHT levels, although reduced, remain sufficient to activate AR [@bib7], [@bib8], [@bib10].

PCa cells have available up to three androgen metabolism pathways to produce DHT [@bib8], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16]. The frontdoor pathway uses the two adrenal androgens, dehydroepiandrosterone (DHEA) and androstenedione (ASD), to synthesize T. DHEA and ASD are synthesized in the adrenal gland using a combination of cytochrome P450 17A1 (CYP17A1) and HSD3B2 enzymes. The terminal step of the frontdoor pathway uses 5α-reductases (SRD5A1, 2, 3) to 5α-reduce T to DHT. The terminal steps of the primary and secondary backdoor pathways do not use T to make DHT. Instead, the primary and secondary backdoor pathways use a combination of SRD5A, CYP17A1 and 3α-oxidoreductase enzymes to produce 5α-androstane-3α,17β-diol (androstanediol) or 5α-androstane-3,17-dione (androstanedione; 5α-dione). The terminal step of the primary backdoor pathway uses 3α-oxidoreductases to oxidize androstanediol to DHT. The secondary backdoor pathway uses 3α-oxidoreductases to reduce 5α-dione to DHT ([Fig. 1](#fig1){ref-type="fig"}). The secondary backdoor pathway, named for its discovery after the primary backdoor pathway, is synonymous with the Sharifi "alternative" [@bib11] and Penning "alternate" [@bib13] backdoor pathways, and Corcoran "5α-dione" pathway [@bib17].Figure 1Pathways to DHT synthesis (modified from Ref. [@bib62]). 5α-reductase (SRD5A) 1, 2 or 3 (frontdoor pathway; pink) metabolize testosterone to dihydrotestosterone (DHT). 3α-oxidoreductase (primary backdoor pathway; purple) or aldo-keto reductase (secondary backdoor pathway; green) enzymes convert androstanediol or androstanedione, respectively to DHT.Figure 1

The goal of this review is to describe the shortcomings of available androgen metabolism inhibitors and to discuss the therapeutic potential of combined inhibition of the 5α-reductases and 3α-oxidoreductases that catalyze the terminal steps of the frontdoor and primary and secondary backdoor pathways for DHT synthesis.

2. CYP17A1 activity, inhibitors and mechanisms of PCa resistance {#sec2}
================================================================

The concept of inhibition of adrenal androgen production began with Huggins and Scott in 1945 [@bib18], who reported that adrenalectomy depleted testicular and adrenal androgens. However, adrenalectomy also produced adrenal insufficiency, which was lethal to patients without glucocorticoid replacement therapy [@bib19], [@bib20]. Since 1945, several adrenal androgen biosynthesis inhibitors were identified, such as aminoglutethimide [@bib21], [@bib22], which impaired 11β-hydroxylase, and ketoconazole [@bib23], [@bib24], [@bib25], which targeted 21- and/or 11β-hydroxylase, 17α-hydroxylase and 17, 20-lyase activity, to deplete circulating adrenal steroid levels, such as DHEA-sulfate [@bib24]. However, aminoglutethimide and ketoconazole were not ideal inhibitors for a number of reasons including drug toxicity [@bib26], [@bib27].

The CYP17A1 inhibitor, abiraterone, impairs both the 17α-hydroxylase and 17,20-lyase activities of the enzyme, thus blocking adrenal androgen synthesis [@bib28], [@bib29]. Abiraterone depletes PCa or CRPC tissue androgen levels and extends patient survival approximately 4 months when used for CRPC, which garnered Food and Drug Administration (FDA) approval [@bib30], [@bib31], [@bib32], [@bib33]. However, inhibition of CYP17A1 by abiraterone can lead to glucocorticoid insufficiency and mineralocorticoid excess. Hypertension, hypokalemia and peripheral edema occur with sufficient frequency that abiraterone is co-administered with prednisone [@bib34], [@bib35], [@bib36].

The earlier clinical failure of abiraterone (and other CYP17A1 inhibitors) has been attributed to several mechanisms that involve AR splice variants [@bib37], circulating DHEA-SO~4~ that remains in spite of abiraterone treatment [@bib38], increased expression of CYP17A1 [@bib39], [@bib40], or other primary [@bib37], [@bib41] and/or secondary backdoor pathway [@bib39] androgen metabolism enzymes. CYP17A1 inhibition induces progesterone accumulation, which competes with abiraterone for CYP17A1 [@bib42]. CYP17A1 inhibition may result in up-regulation of CYP11A1 and the aldo-keto reductase family 1 member C3 (AKR1C3); both enzymes are capable of increasing intra tumoral *de novo* androgen synthesis by activating different androgen metabolism pathways [@bib42]. Chang et al. [@bib43] reported HSD3B1 mutations promote DHT synthesis despite therapeutic intervention. The concept of interrupting intratumoral androgen metabolism has merit, but CYP17A1 inhibition occurs too early in the DHT synthesis pathways, which enables PCa cells to alter the pathways used to produce DHT.

Therefore, inhibition of the terminal steps of the primary and secondary backdoor pathways using a combination of SRD5A and 3α-oxidoreductase enzyme inhibitors may improve PCa response. Inhibition of the steps immediately proximal to DHT synthesis will render pathway switching ineffective, which may lower DHT levels better than any androgen metabolism inhibitor used alone.

3. 5α-reductase inhibition alone is insufficient to deplete intratumoral DHT levels {#sec3}
===================================================================================

The 5α-reductases (types I--III) encoded by SRD5A1, 2 or 3 play an essential role in metabolism of progestagens, glucocorticoids and androgens. These enzymes irreversibly reduce the double bond at C4 and C5 in Ring A ([Fig. 2](#fig2){ref-type="fig"}; purple) [@bib44], [@bib45], [@bib46] of substrates such as progesterone, cortisolor T, to produce dihydroprogesterone, dihydrocortisolor DHT, respectively [@bib46]. The type II reductase encoded by SRD5A2 is predominant in benign hyperplastic prostate and is the target of finasteride. Dutasteride inhibits type I and type II 5α-reductase, and may also inhibit type III as well [@bib47]. PCa may depend more on SRD5A1 and SRD5A3 [@bib48]. Finasteride treatment enhanced the extent of response to ADT when initiated simultaneously with ADT [@bib49], [@bib50], [@bib51], [@bib52], [@bib53], which suggests 5α-reductase inhibition may be useful when used earlier for advanced PCa. However, finasteride and dutasteride both have proven ineffective in CRPC because of variable patient response, accumulation of T that enables AR activation, and/or insufficient depletion of intratumoral DHT levels due to active SRD5A3 or primary or secondary backdoor pathway metabolism [@bib54], [@bib55], [@bib56], [@bib57].Figure 25α-reductase (SRD5A) (blue) and 3α-oxidoreductase (oxidation \[purple\]; reduction \[red\]) target sites on steroid rings. SRD5A activity (blue) occurs at the 5α position of Ring A, 3α-oxidoreductase oxidation sites (purple) occur at the 3α position of Ring A and aldo-keto reduction (red) occurs at the 17β position of Ring D.Figure 2

4. 3α-oxidoreductases inhibition lowers intratumoral DHT levels *in vitro* {#sec4}
==========================================================================

Redox enzymes, such as hydroxysteroid dehydrogenases (HSD), aldo-keto reductases or retinol dehydrogenases (RDH) oxidize or reduce steroid substrates [@bib8], [@bib9], [@bib58]. These enzymes are responsible for steroid metabolism, which includes glucocorticoid, mineralocorticoid and androgen synthesis or degradation [@bib59], [@bib60], [@bib61].

The terminal step in the primary backdoor pathway of androgen metabolism uses one of four 3α-oxidoreductases (HSD17B6; RDH5; RDH16; and dehydrogenase/reductase family member 9 \[DHRS9\]) to convert androstanediol to DHT [@bib8], [@bib62]. The 3α-oxidoreductases have conserved catalytic amino acids ([Fig. 3](#fig3){ref-type="fig"}) and co-factor binding sites [@bib63], [@bib64], [@bib65], [@bib66], and carry out similar reactions, despite having different K~m~ values [@bib62], [@bib67]. Preclinical studies using castration-recurrent CWR-R1 human xenografts demonstrated that androstanediol is converted to DHT [@bib68]. The secondary backdoor pathway requires a combination of SRD5A, to 5α-reduce ASD to 5α-dione, the four 3α-oxidoreductases, AKR1C3 or HSD17B3, to finally reduce 5α-dione to DHT [@bib11], [@bib12], [@bib13], [@bib17].Figure 3Sequence alignment of the four 3α-oxidoreductases showed that their catalytic amino acid residues are conserved (green box). COBALT protein sequence alignment shows the conserved catalytic amino acid residues among the four 3α-oxidoreductases.Figure 3

A pre-clinical study using the AKR1C3 inhibitor, indomethacin, demonstrated a proof of principle that AKR1C3 inhibition overcame PCa resistance to abiraterone and enzalutamide. The study provided evidence for the necessity for identification and development of AKR1C3 inhibitors [@bib13], [@bib69]. A Phase 1/2 clinical trial that tested the efficacy of an AKR1C3 inhibitor, ASP9521, ended without evidence of clinical response. The authors suggested that insufficient PCa cell expression of AKR1C3 may have caused therapeutic failure [@bib70].

No 3α-oxidoreductase inhibitors are used in the clinic to inhibit the four enzymes that metabolize androstanediol to DHT or 5α-dione to DHT. Recently, our group showed that combined inhibition of the four 3α-oxidoreductases and SRD5A1 or SRD5A2 lowered DHT levels better than inhibition of either enzyme group alone using *in vitro* PCa cell line models [@bib62].

One challenge with using 3α-oxidoreductase inhibition therapy is enzyme redundancy. Dutasteride treatment and expression of catalytically inactive 3α-oxidoreductases impaired PCa cell line production of DHT, but did not reduce DHT levels completely in all experimental conditions [@bib62]. Expression data showed that clinical PCa specimens and PCa cell lines express at least one or more 3α-oxidoreductase enzymes [@bib62]. Inhibition of one 3α-oxidoreductase enzyme may impair DHT production, but remain insufficient to deplete DHT levels and inactivate AR. An ideal inhibitor would target all four 3α-oxidoreductases. However, the enzymes have low protein sequence homology. This implies that there are variations in the precise substrate recognition regions of the enzymes despite their sharing 100% identity among their catalytic residues [@bib62], [@bib63].

Finally, the role of post-translational modification and activity regulation in 3α-oxidoreductase remains unclear in clinical prostate specimens. These regulators of 3α-oxidoreductase activity may provide an alternative target for catalytic inhibition.

5. Conclusion {#sec5}
=============

The inhibition of androgen metabolism enzymes to improve PCa response to ADT or impair or prolong PCa transition to CRPC has merit. Despite success with CYP17A1 inhibition (an upstream androgen metabolism enzyme), PCa recurs or CRPC persists during treatment and remains lethal [@bib37], [@bib39], [@bib40], [@bib41]. Inhibition of SRD5A to block the terminal step of the frontdoor pathway (conversion of T to DHT) has proven ineffective against CRPC [@bib55], [@bib56], [@bib57]. AKR1C3 inhibition also has been unsuccessful [@bib70]. Inhibition of the enzymes that catalyze terminal stepsin the primary backdoor androgen metabolism (conversion androstanediol to DHT) or the secondary backdoor androgen metabolism pathways (conversion androstanedione to DHT) has not been tested clinically because of a lack of candidate inhibitors.

Once inhibitors of the four 3α-oxidoreductases are developed, the lead candidate can be tested alone or combined with ADT, CYP17A1 and SRD5A1 inhibitors ([Fig. 4](#fig4){ref-type="fig"}) in order to impair upstream and downstream androgen metabolism and thereby minimize the ability of PCa cells to adapt their androgen metabolism pathways during ADT. This therapy is similar to the proposed androgen annihilation therapy [@bib71], however, this new "complete" androgen annihilation includes 3α-oxidoreductase inhibition to impair both terminal steps of the primary and secondary backdoor androgen metabolism pathways. 3α-oxidoreductase inhibition may need to be combined with anti-androgens or AR splice variant therapeutics if 3α-oxidoreductase inhibition alone reveals AR is stimulated despite inhibition of the backdoor pathway or if AR-splice variants develop. Complete androgen annihilation should improve ADT and delay or prevent death from CRPC.Figure 4Model of a coordinated attack on enzymes that drive dihydrotestosterone (DHT) production that should lower DHT levels better than an upstream attack of any specific enzyme. Androgen metabolism inhibitors against CYP17A1, 3α-oxidoreductase, aldo-keto reductase and SRD5A used simultaneously should lower DHT levels better than individual enzyme inhibition alone. CYP17A1, cytochrome P450 17A; SRD5A, 5-reductases; 3α-OR, 3α-oxidoreductase.Figure 4
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